We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
(+22%)
Cap. Flow
+$1.16B
Cap. Flow
% of AUM
36.62%
Top 10 Holdings %
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$37.9M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$24.5M |
| 3 |
Merck
MRK
|
+$12.3M |
| 4 |
Gilead Sciences
GILD
|
+$11.7M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$16.4M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$9.99M |
| 3 |
Tesla
TSLA
|
+$7.93M |
| 4 |
Larimar Therapeutics
LRMR
|
+$4.64M |
| 5 |
Ocular Therapeutix
OCUL
|
+$3.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 89.52% |
| 2 | Healthcare | 9.63% |
| 3 | Energy | 0.42% |
| 4 | Industrials | 0.14% |
| 5 | Consumer Staples | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OCRX
101
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $2.74M | 0.09% |
+429,945
| New | +$2.52M |
|
102
PUT
Precigen
PGEN
$2.49B
| $2.72M | 0.09% |
1,033
-13
| -1% | -$285 |
|
|
ASPX
103
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $2.62M | 0.08% |
50,000
-70,000
| -58% | -$2.06M |
|
|
AKTX
104
Akari Therapeutics
AKTX
$20.1M
| $2.59M | 0.08% |
67
-41
| -38% | -$1.79M |
|
|
TTOO
105
DELISTED
T2 Biosystems, Inc
TTOO
| $2.57M | 0.08% |
27
+6
| +29% | +$495K |
|
|
LITS
106
Lite Strategy Inc
LITS
$36.4M
| $2.56M | 0.08% |
30,000
+16,814
| +128% | +$2.21M |
|
|
RGLS
107
CALL
DELISTED
Regulus Therapeutics
RGLS
| $2.5M | 0.08% |
+92
| New | +$164K |
|
108
TherapeuticsMD
TXMD
$25M
| $2.45M | 0.08% |
+10,997
| New | +$2.27M |
|
|
DRNA
109
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.4M | 0.08% |
145,919
-114,081
| -44% | -$1.32M |
|
110
CALL
Teva Pharmaceuticals
TEVA
$45.5B
| $2.39M | 0.08% |
416
-628
| -60% | -$35K |
|
111
Trupanion
TRUP
$1.18B
| $2.39M | 0.08% |
345,205
+110,205
| +47% | +$723K |
|
|
112
Ocular Therapeutix
OCUL
$2.28B
| $2.33M | 0.07% |
98,951
-198,156
| -67% | -$3.33M |
|
113
Community Health Systems
CYH
$416M
| $2.32M | 0.07% |
+52,063
| New | +$2.23M |
|
|
CRDC
114
DELISTED
CARDICA INC COM NEW (DE)
CRDC
| $2.2M | 0.07% |
314,666
+212,752
| +209% | +$1.75M |
|
|
SCTL
115
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $2.2M | 0.07% |
856,137
+546,722
| +177% | +$1.38M |
|
|
ALBO
116
DELISTED
Albireo Pharma Inc
ALBO
| $2.15M | 0.07% |
53,838
+4,078
| +8% | +$179K |
|
|
RXDX
117
DELISTED
Ignyta, Inc.
RXDX
| $2.13M | 0.07% |
311,191
+81,490
| +35% | +$554K |
|
|
NPSP
118
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $2.13M | 0.07% |
594
+94
| +19% | +$2.81K |
|
119
CALL
Novavax
NVAX
$1.53B
| $2.06M | 0.07% |
+174
| New | +$18.2K |
|
|
FOLD
120
DELISTED
Amicus Therapeutics
FOLD
| $2.05M | 0.06% |
+246,697
| New | +$1.69M |
|
|
SHPG
121
DELISTED
Shire pic
SHPG
| $2.05M | 0.06% |
9,652
-303
| -3% | -$64.3K |
|
122
PUT
Incyte
INCY
$24.6B
| $2M | 0.06% |
+273
| New | +$17.8K |
|
|
TSRO
123
CALL
DELISTED
TESARO, Inc.
TSRO
| $1.99M | 0.06% |
534
-1,073
| -67% | -$33.1K |
|
124
Savara
SVRA
$1.08B
| $1.98M | 0.06% |
+50,568
| New | +$1.77M |
|
|
XOMA
125
CALL
DELISTED
Xoma
XOMA
| $1.98M | 0.06% |
275
+120
| +77% | +$10.3K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q4 2014 Portfolio in Review
As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.
- Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
- Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
- Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
- Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
- Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
- Sabby Management opened 68 new positions and closed 84 in Q4 2014.
- Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.
Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.